TheStreet.com Stocks Under $10

Trimming a Pharmaceutical Position

twocents@thestreet.com (David Peltier) — Wed, 22 May 2013 14:27 GMT

The stock has doubled over the past three months and we don't want to be greedy with our gains.

Ask SUT

twocents@thestreet.com (David Peltier) — Tue, 21 May 2013 16:07 GMT

This week, David Peltier answers questions about choosing stocks to add to the model portfolio and exiting positions.

Stocks Under $10 Weekly Summary

twocents@thestreet.com (David Peltier) — Fri, 17 May 2013 20:34 GMT

We used the strength this week to take some profits in three model portfolio positions, and we added to two other holdings.

Buying and Selling

twocents@thestreet.com (David Peltier) — Fri, 17 May 2013 15:18 GMT

We are trimming our position in a software name and using some of the gains to build up our holding in a mining company.

Positive Update for a Semiconductor

twocents@thestreet.com (David Peltier) — Wed, 15 May 2013 19:22 GMT

This name is trading higher today following management's announcement of a $75 million stock repurchase program.

VIDEO: Deconstructing a Housing Stock

twocents@thestreet.com (David Peltier) — Wed, 15 May 2013 17:13 GMT

Builders FirstSource is a hot low-dollar stock. David Peltier and Lindsey Bell discuss if it's still a buy.

Making and Spending Some Gains

twocents@thestreet.com (David Peltier) — Wed, 15 May 2013 16:48 GMT

We are selling a portion of one position and rolling the profits into purchasing more shares to add to another holding.

Ask SUT

twocents@thestreet.com (David Peltier) — Tue, 14 May 2013 15:48 GMT

This week, David Peltier answers a question about how long to hold a stock and another on the history of a specific name.

Purchases Boost Two Holdings

twocents@thestreet.com (David Peltier) — Mon, 13 May 2013 15:51 GMT

Reports of recent insider buying at these two model portfolio names are lifting their shares today. Here are the details.

Cashing In on Continuing Strength

twocents@thestreet.com (David Peltier) — Mon, 13 May 2013 13:39 GMT

Shares of this medical instruments supplier keep pushing higher so we booking some gains and changing our rating to a Two.

Stocks Under $10 Weekly Summary

twocents@thestreet.com (David Peltier) — Fri, 10 May 2013 20:28 GMT

As earnings season wrapped up this week, we added shares to one model portfolio position and trimmed one other.

Driller Posts Mixed Results

twocents@thestreet.com (David Peltier) — Fri, 10 May 2013 15:46 GMT

But with global demand growing for its services increasing, this name's shares are attractive to purchase on pullbacks.

Disappointing Results Sink Shares

twocents@thestreet.com (David Peltier) — Fri, 10 May 2013 14:29 GMT

Despite the earnings miss, we believe the stock remains undervalued, given the company's pristine balance sheet.

Increased Demand Drives Upside

twocents@thestreet.com (David Peltier) — Fri, 10 May 2013 14:14 GMT

This pharmaceutical name is trading higher this morning on news of its better-than-expected quarterly results.

Shares Surge After Earnings

twocents@thestreet.com (David Peltier) — Fri, 10 May 2013 13:58 GMT

News that the company is poised to sign a big deal with a large pharmaceutical partner is driving the upside.

Early Morning Earnings Calls

twocents@thestreet.com (David Peltier) — Thu, 09 May 2013 19:50 GMT

Here is what we'll be focusing on when this theatrical equipment supplier and drilling name report on Friday.

A Pair of Earnings Previews

twocents@thestreet.com (David Peltier) — Thu, 09 May 2013 19:38 GMT

Here are the updates that we'll be listening for when these two companies report later today and tomorrow morning.

Taking Profits in a Semi Holding

twocents@thestreet.com (David Peltier) — Thu, 09 May 2013 17:40 GMT

We are also lowering our rating on the name.

Earnings Produce Few Surprises

twocents@thestreet.com (David Peltier) — Thu, 09 May 2013 15:27 GMT

This pharmaceuticals name posted solid quarterly results today, we believe its new products can continue to drive growth.

Making a Post-Earnings Purchase

twocents@thestreet.com (David Peltier) — Thu, 09 May 2013 15:09 GMT

This drugmaker is trading lower on disappointing quarterly results, so we are using the weakness to add to our position.